Add to ORKGAbstract RVX 208 (RVX-208; RVX000222) is a first-in-class novel small molecule in development by Resverlogix Corporation for acute coronary syndromes, atherosclerosis and Alzheimer disease. It increases the levels of apolipopro-tein A1 and high-density lipoprotein cholesterol, thereby potentially reducing the risk for cardiovascular disease. This review discusses the key development milestones and therapeutic trials of this drug. 1
AIMS: High-density lipoprotein (HDL) and apolipoprotein A-I (apoA-I) can modulate glucose metabolis...
A non-resolving inflammation results in a chronic inflammatory response, characteristic of atheroscl...
Atherosclerotic cardiovascular diseases (ASCVD) are still the leading cause of morbidity and mortali...
Introduction: RVX-208 is a first-in-class, orally active, novel small molecule in development by Res...
ObjectivesThe aim of this study was to determine whether a novel small molecule RVX-208 affects apol...
AbstractHigh density lipoproteins (HDL), through activity of the main protein component apolipoprote...
Bromodomain and extra-terminal (BET) proteins regulate transcription of lipoprotein and inflammatory...
Atherosclerosis, the underlying process that ultimately leads to clinical cardiovascular disease (CV...
Dyslipidaemia is a major risk factor for cardiovascular diseases. Pharmacological lowering of LDL-C ...
Increased synthesis of Apolipoprotein A-I (ApoA-I) and HDL is believed to provide a new approach to ...
BACKGROUND: Bromodomain and extra-terminal (BET) proteins regulate transcription of lipoprotein and...
Apabetalone (RVX-208) inhibits the interaction between epigenetic regulators known as bromodomain an...
Atherosclerosis, a disease which affects large and medium sized arteries, is now a leading cause of ...
Introduction: Dyslipidemia is increased fasting level of total cholesterol (TC), LDL cholesterol (LD...
Remarkably good results have been achieved in the treatment of atherosclerotic cardiovascular diseas...
AIMS: High-density lipoprotein (HDL) and apolipoprotein A-I (apoA-I) can modulate glucose metabolis...
A non-resolving inflammation results in a chronic inflammatory response, characteristic of atheroscl...
Atherosclerotic cardiovascular diseases (ASCVD) are still the leading cause of morbidity and mortali...
Introduction: RVX-208 is a first-in-class, orally active, novel small molecule in development by Res...
ObjectivesThe aim of this study was to determine whether a novel small molecule RVX-208 affects apol...
AbstractHigh density lipoproteins (HDL), through activity of the main protein component apolipoprote...
Bromodomain and extra-terminal (BET) proteins regulate transcription of lipoprotein and inflammatory...
Atherosclerosis, the underlying process that ultimately leads to clinical cardiovascular disease (CV...
Dyslipidaemia is a major risk factor for cardiovascular diseases. Pharmacological lowering of LDL-C ...
Increased synthesis of Apolipoprotein A-I (ApoA-I) and HDL is believed to provide a new approach to ...
BACKGROUND: Bromodomain and extra-terminal (BET) proteins regulate transcription of lipoprotein and...
Apabetalone (RVX-208) inhibits the interaction between epigenetic regulators known as bromodomain an...
Atherosclerosis, a disease which affects large and medium sized arteries, is now a leading cause of ...
Introduction: Dyslipidemia is increased fasting level of total cholesterol (TC), LDL cholesterol (LD...
Remarkably good results have been achieved in the treatment of atherosclerotic cardiovascular diseas...
AIMS: High-density lipoprotein (HDL) and apolipoprotein A-I (apoA-I) can modulate glucose metabolis...
A non-resolving inflammation results in a chronic inflammatory response, characteristic of atheroscl...
Atherosclerotic cardiovascular diseases (ASCVD) are still the leading cause of morbidity and mortali...